StockData
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30
$76.80−0.56 (-0.72%)

Close on Nov 17, 2026Market cap $14.96BP/E –Yield –

BridgeBio Pharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

BridgeBio Pharma's revenue for the twelve months ending Sep 30, 2026 was $945.54M, up 167.3% year over year. For fiscal 2025 it was $502.08M, up 126.3% from the year before. The highest annual figure on record is $502.08M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$502.08M+126.3%
FY2024Dec 31, 2024$221.90M+2285.3%
FY2023Dec 31, 2023$9.30M-88.0%
FY2022Dec 31, 2022$77.65M+11.4%
FY2021Dec 31, 2021$69.72M+745.1%
FY2020Dec 31, 2020$8.25M-79.7%
FY2019Dec 31, 2019$40.56M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$353.17M+192.6%
Q2 FY2026Jun 30, 2026$243.68M+120.4%
Q1 FY2026Mar 31, 2026$194.52M+66.8%
Q4 FY2025Dec 31, 2025$154.18M+2521.2%
Q3 FY2025Sep 30, 2025$120.70M+4318.0%
Q2 FY2025Jun 30, 2025$110.57M+4999.9%
Q1 FY2025Mar 31, 2025$116.63M-44.8%
Q4 FY2024Dec 31, 2024$5.88M+237.1%
Q3 FY2024Sep 30, 2024$2.73M-33.2%
Q2 FY2024Jun 30, 2024$2.17M+32.1%
Q1 FY2024Mar 31, 2024$211.12M+11461.9%
Q4 FY2023Dec 31, 2023$1.75M-6.7%
Q3 FY2023Sep 30, 2023$4.09M+1110.4%
Q2 FY2023Jun 30, 2023$1.64M-97.8%
Q1 FY2023Mar 31, 2023$1.83M+7.8%
Q4 FY2022Dec 31, 2022$1.87M-85.5%
Q3 FY2022Sep 30, 2022$338.00K-85.6%
Q2 FY2022Jun 30, 2022$73.75M+36.5%
Q1 FY2022Mar 31, 2022$1.69M+266.7%
Q4 FY2021Dec 31, 2021$12.89M+10462.3%
Q3 FY2021Sep 30, 2021$2.34M-71.2%
Q2 FY2021Jun 30, 2021$54.02M+290.9%
Q1 FY2021Mar 31, 2021$462.00K-98.3%
Q4 FY2020Dec 31, 2020$122.00K–
Q3 FY2020Sep 30, 2020$8.13M–
Q4 FY2019Dec 31, 2019$13.82M–
Q3 FY2019Sep 30, 2019$26.74M–

More BridgeBio Pharma figures

See a number that looks wrong?